Who are ketotifen fumarate 0.025% eye drops's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone furoate and fexofenadine, Morphine-Promethazine, olopatadine (OLO), Fluticasone/Azelastine nasal spray, alcaftadine 0.25% ophthalmic solution, Atarax (Hydroxyzine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketotifen-fumarate-0-025-eye-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

ketotifen fumarate 0.025% eye drops — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ketotifen fumarate 0.025% eye drops (ketotifen fumarate 0.025% eye drops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antihistamine. Area: Ophthalmology.

phase 3 Antihistamine Histamine receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

ketotifen fumarate 0.025% eye drops (ketotifen fumarate 0.025% eye drops) — Campus Bio-Medico University. Ketotifen fumarate is an antihistamine that works by blocking histamine receptors in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ketotifen fumarate 0.025% eye drops TARGET	ketotifen fumarate 0.025% eye drops	Campus Bio-Medico University	phase 3	Antihistamine	Histamine receptor
Fluticasone furoate and fexofenadine	Fluticasone furoate and fexofenadine	GlaxoSmithKline	marketed	Intranasal corticosteroid and antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
Morphine-Promethazine	Morphine-Promethazine	Tel-Aviv Sourasky Medical Center	marketed	Opioid analgesic combination	Mu-opioid receptor (morphine); H1 histamine receptor (promethazine)
olopatadine (OLO)	olopatadine (OLO)	University of Chicago	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
Atarax (Hydroxyzine)	Atarax (Hydroxyzine)	University Hospital, Toulouse	marketed	First-generation H1 antihistamine	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antihistamine class)

· 1 drug in this class
Allergan · 1 drug in this class
Campus Bio-Medico University · 1 drug in this class
Chattem · 1 drug in this class
Erasmus Medical Center · 1 drug in this class
Ministry Of Health / Nineveh Health Directorate · 1 drug in this class
Pfizer · 1 drug in this class
UCB Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketotifen fumarate 0.025% eye drops — Competitive Intelligence Brief. https://druglandscape.com/ci/ketotifen-fumarate-0-025-eye-drops. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab